Case Report

Fusarium oxysporum Pneumonia in an Immunocompetent Host

Authors: Stephen R. Gorman, DO, MSC, Anna-Pelagia Magiorakos, MD, Sarah K. Zimmerman, MED, Donald E. Craven, MD

Abstract

Abstract:A case of symptomatic pulmonary infection caused by Fusarium oxysporum occurred in a woman after she had cleaned out bird droppings from a boat house. She was also a gardener who had mild, chronic obstructive lung disease, but who had no evidence of systemic immunosuppression. She was treated with oral voriconazole for four months and had marked clinical improvement and mycological cure. To the best of our knowledge, this is the first reported case of isolated pulmonary fusariosis in an apparently immunocompetent person. Oral voriconazole therapy was effective in this clinical setting.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Lionakis MS, Kontoyiannis DP. Fusarium infections in critically ill patients. Semin Respir Crit Care Med 2004;25:159–169.
 
2. Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 2004;10(Suppl. 1):48–66.
 
3. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect. 2004;10(Suppl. 1):67–75
 
4. Fleming RV, Walsh TJ, Anaissie EJ. Emerging and less common fungal pathogens. Infect Dis Clin N Amer 2002;16:915–933.
 
5. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood1997;90:999–1008.
 
6. Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003;98:315–319.
 
7. Arney KL, Tiernan R, Judson MA. Primary pulmonary involvement of Fusarium solani in a lung transplant recipient. Chest 1997;112:1128–1130.
 
8. Zach TL, Penn RG, Gnarra DJ, et al. Fusarium moniliforme pneumonia. Nebr Med J 1987;72:6–9.
 
9. Kurien M, Anandi V, Raman R, et al. Maxillary sinus fusariosis in immunocompetent hosts. J Laryngol Otol 1992;106:733–736.
 
10. Espinel-Ingroff A. Utility of mould susceptibility testing. Curr Opin Infect Dis 2003;16:527–532.
 
11. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 2002;46:3298–3300.
 
12. Rodriguez CA, Luján-Zilbermann J, Woodard P, et al. Successful treatment of disseminated fusariosis. Bone Marrow Transplant 2003;31:411–412.
 
13. Consigny S, Dhedin N, Datry A, et al. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient. Clin Infect Dis 2003;37:311–313.
 
14. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122–1131.